CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of colorectal cancer.
  
  LEARNING OBJECTIVES

  • Develop an understanding of validated biomarkers of response in CRC, such as RAS mutations, microsatellite instability (MSI)/mismatch repair (MMR) deficiency, HER2 overexpression and BRAF V600E mutations, and consider the implications for molecular testing and clinical care.
  • Optimize the use of neoadjuvant and adjuvant systemic therapy for patients with localized CRC, considering various clinical and biological factors, such as age, performance status, disease stage and MSI/MMR status, and the potential relevance of molecular residual disease.
  • Formulate a plan to guide the selection and sequencing of therapy for patients diagnosed with metastatic CRC (mCRC), accounting for tumor sidedness, biomarker profile, prior systemic therapy, symptomatology and personal goals of treatment.
  • Evaluate the biological rationale for the use of immune checkpoint inhibitors in the treatment of localized and advanced MSI-high/MMR-deficient CRC, and counsel patients regarding evidence-based and guideline-endorsed treatment recommendations.
  • Appreciate published research documenting the efficacy of targeted therapeutic approaches for patients with mCRC and various actionable genomic alterations, and use this information to personalize treatment recommendations.
  • Recall ongoing trials evaluating novel agents and strategies for CRC, and use this information to refer patients for study participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 2.75 (audio) and 2.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
  Successful completion of these CME activities, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASCO2025/CRC/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/ASCO2025/CRC/Video.
  
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASCO2025/CRC/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/ASCO2025/CRC.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Andrea Cercek, MD
  Section Head, Colorectal Cancer
  Co-Director, Center for Young Onset Colorectal and Gastrointestinal Cancers
  Attending, Gastrointestinal Oncology Service
  Department of Medicine
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Advisory Boards: 3T Biosciences, AbbVie Inc, Agents, Amgen Inc, Daiichi Sankyo Inc, GSK, Janssen Biotech Inc, Merck, Pfizer Inc, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Summit Therapeutics, UroGen Pharma; Contracted Research: GSK, Pfizer Inc.
  
  Arvind Dasari, MD, MS
  Professor
  Department of Gastrointestinal Medical Oncology
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committees: Agenus Inc, Bristol Myers Squibb, Exelixis Inc, Illumina, Lantheus, Personalis, Sanofi, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Bristol Myers Squibb, Crinetics Pharmaceuticals, Eisai Inc, Enterome, Guardant Health, Hutchison MediPharma, Natera Inc, NeoGenomics, Personalis, RayzeBio Inc, Taiho Oncology Inc, Xencor.
  
  Pashtoon Kasi, MD, MS
  Medical Director of GI Oncology
  Endowed Rad Family Chair in Gastrointestinal Oncology
  Associate Professor
  Department of Medical Oncology and Therapeutics Research
  City of Hope Orange County
  Irvine, California
  
  Advisory Committees: Elicio Therapeutics; Consulting Agreements: Agenus Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bexion Pharmaceuticals, BostonGene, Daiichi Sankyo Inc, Delcath Systems Inc, Eisai Inc, Exact Sciences Corporation, Foundation Medicine, Guardant Health, Illumina, Lilly, Merck, MSD, Natera Inc, NeoGenomics, QED Therapeutics, Regeneron Pharmaceuticals Inc, SAGA Diagnostics, Seagen Inc, Servier Pharmaceuticals LLC, Taiho Oncology Inc, Tempus, Xilio Therapeutics; Contracted Research: Agenus Inc, Merck, Novartis; Stock Options/Stock — Public Companies: Elicio Therapeutics.
  
  Eric Van Cutsem, MD, PhD
  Professor of Medicine
  Digestive Oncology
  University Hospitals Leuven
  Leuven, Belgium
  
  Advisory Committees: AbbVie Inc, Agenus Inc, ALX Oncology, Amgen Inc, Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BioNTech SE, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Cantargia AB (CANFOUR trial), Daiichi Sankyo Inc, Debiopharm, Eisai Inc, ElmediX, Galapagos NV, GSK, Hookipa Pharma Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck KGaA, Mirati Therapeutics Inc, MSD, Nordic Pharma, Novartis, Pfizer Inc, Pierre Fabre, Roche Laboratories Inc, Seagen Inc, Servier Pharmaceuticals LLC, Simcere, Taiho Oncology Inc, Takeda Pharmaceutical Company Limited, Terumo Medical Corporation; Nonrelevant Financial Relationships: Bexon Clinical Consulting.
  
  MODERATOR
  J Randolph Hecht, MD
  Professor of Clinical Medicine
  Director, UCLA GI Oncology Program
  Carol and Saul Rosenzweig Chair in Cancer Therapies
  Development
  UCLA David Geffen School of Medicine
  Santa Monica, California
  
  Advisory Committees: Actym Therapeutics, MBQ Pharma, Radical AI, Triumvira Immunologics; Consulting Agreements: BeiGene Ltd, Hexagon Bio, Parabilis Medicines, Revolution Medicines, UroGen Pharma, Xilio Therapeutics; Contracted Research: A2 Bio, Affini-T Therapeutics, Agenus Inc, AstraZeneca Pharmaceuticals LP, Bold Therapeutics, Camurus, CG Invites, Crinetics Pharmaceuticals, Exelixis Inc, Gilead Sciences Inc, Gritstone bio, GSK, IGM Biosciences Inc, Janssen Biotech Inc, Mirati Therapeutics Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines, Tizona Therapeutics Inc, Xilio Therapeutics; Stock Options — Private Companies: Actym Therapeutics, Radical AI, Triumvira Immunologics.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from GSK and Natera Inc.
  
  Release date: June 2025
  Expiration date: June 2026
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.